This new imagingbiomarker can be used as a complement to conventional prognostic biomarkers such as PSA,GS and cT to stratify high-risk prostate cancer patients, not only at the time ofdiagnosis but also during later stages of the disease. This evidence concerns the gene KLK3 and prostate cancer.